Recruiting PHASE4 INTERVENTIONAL 2-arm NCT05624190

Intra-arterial Recombinant Human TNK Tissue-type Plasminogen Activator (rhTNK-tPA) Thrombolysis for Acute Large Vascular Occlusion After Successful Mechanical Thrombectomy Recanalization (ANGEL-TNK)

Intra-arterial Recombinant Human Tenecteplase Tissue-type Plasminogen Activator rhTNK-tPA) Thrombolysis for Acute Large Vessel Occlusion After Successful Mechanical Thrombectomy Recanalization -- A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial (ANGEL-TNK)

Sponsor: Beijing Tiantan Hospital

Conditions Ischemic Stroke, Acute

Interventions Best Medical Management Recombinant Human tenecteplase Tissue-type Plasminogen Activator (rhTNK-tPA)

Updated 4 times since 2022 Last updated: Mar 18, 2024 Started: Feb 16, 2023 Primary completion: Jul 31, 2024 Completion: Jul 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Ischemic Stroke, Acute and is currently actively recruiting participants. Beijing Tiantan Hospital leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE4
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE4
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE4

Status: Not Yet Recruiting → Recruiting
Dec 2022 — Apr 2024 [monthly]

Not Yet Recruiting PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Beijing Tiantan Hospital

Data source: Beijing Tiantan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China